GORE EXCLUDER Conformable AAA Endoprosthesis (EXCC) 00733132650927; 00733132650934; 00733132650941; 00733132650958; 00
W. L. Gore and Associates, Inc. · Decision date Aug 29, 2025
What did the FDA decide?
FDA records P200030/S022 as a supplement to PMA P200030, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 29, 2025.
FDA approval order statement
a manufacturing facility move for a supplier of delivery system components for the GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CMDS) and GORE EXCLUDER Conformable AAA Endoprosthesis (EXCC)
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 29, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200030/S022
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore and Associates, Inc.
- Product code
- MIH
- Decision code
- OK30
- Decision date
- Aug 29, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.
- Applicant
- W. L. Gore and Associates, Inc.
- Product code
- MIH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P200030/S022 received
Application receipt date recorded by FDA.
P200030/S022 · FDA decision
30-Day Notice
P200030/S023 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis
P200030/S024 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis
P200030/S025 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis
P200030/S026 · Related supplement
GORE EXCLUDER Conformable AAA Endoprosthesis
Timeline entries are records held by MedtechLedger for P200030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GORE EXCLUDER Conformable AAA EndoprosthesisP200030/S023 | W. L. Gore and Associates, Inc. | PMA supplement | Dec 5, 2025 | FDA |
GORE EXCLUDER Conformable AAA EndoprosthesisP200030/S024 | W. L. Gore and Associates, Inc. | PMA supplement | May 14, 2026 | FDA |
GORE EXCLUDER Conformable AAA EndoprosthesisP200030/S025 | W. L. Gore and Associates, Inc. | PMA supplement | Jul 8, 2026 | FDA |
GORE EXCLUDER Conformable AAA EndoprosthesisP200030/S026 | W. L. Gore and Associates, Inc. | PMA supplement | Jul 29, 2026 | FDA |
Explore the linked device profile
Other records with product code MIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPro Thoracic Stent-Graft Delivery SystemP200045/S025 | Bolton Medical, Inc. | PMA supplement | Oct 28, 2026 | FDA |
| Cook, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Cook, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Cook Medical Incorporated | PMA supplement | Aug 4, 2026 | FDA | |
| William Cook Europe Aps | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore and Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 32360 N. N. Valley Pkwy., Phonix, AZ, 85085
Sources and methodology
- Original FDA record: P200030/S022
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




